Remarkable Long-term Outcomes for Palbociclib-based Regimens for HR+/HER- Advanced Breast Cancer

In this MEDtalk, Professor Antonio Llombart Cussac from Hospital Arnau de Vilanova in Spain presents the results from the extended follow-up of palbociclib in combination with fulvestrant or letrozole for endocrine-sensitive, hormone receptor–positive/HER2-negative advanced breast cancer, derived from the PARSIFAL study.

The study demonstrates, among other findings, the notable antitumor activity of palbociclib-based treatment regimens. Furthermore, the results confirm that no significant difference exists between fulvestrant and letrozole when combined with palbociclib in the treatment of HR-positive/HER2-negative advanced breast cancer.